经过生活方式干预后,老年人有记忆障碍和轻度认知障碍的记忆改善:一项不受控制的试验
Zihan Ding1, Tiffany Wing-Yin Pang2, Agnes S Chan1,2
1Neuropsychology Laboratory, Department of Psychology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Journal of Alzheimer's disease : JAD
|July 21, 2025
概括
使用智能手机应用程序进行为期一个月的生活方式医学计划显著改善了老年人患阿尔茨海默病 (AD) 风险的记忆力,特别是那些有轻度认知障碍 (MCI) 或主观记忆障碍 (SMC) 的老年人.
科学领域:
- 老年学是指老年学的学科.
- 神经学 神经学
- 数字健康数字健康
背景情况:
- 阿尔茨海默病 (AD) 与可修改的生活方式因素有关.
- 生活方式干预提供了预防或延迟AD的潜在策略.
研究的目的:
- 评估一个月的智能手机应用程序辅助的生活方式医学计划是否可以提高老年人患AD风险的记忆力.
- 评估该计划对主观记忆障碍 (SMC) 和轻度认知障碍 (MCI) 患者的影响.
主要方法:
- 158名60-80岁的成年人参与了这项研究,包括正常认知 (NC),SMC和MCI组.
- 参与者参加了每周的研讨会和每天的应用程序指导的家庭作业.
- 使用香港列表学习测试 (HKLLT) 测量了口头学习和记忆,干预前后.
主要成果:
- 在干预后,各组观察到学习和记忆的显著改善,MCI组显示出最大的益处.
- 临床上显著改善的口头记忆被注意到在94%的amnestic MCI病例.
- 很大比例的MCI (57-77%) 和SMC (54-63%) 参与者符合可靠和临床显著的变化标准.
结论:
- 智能手机应用程序支持的生活方式医学计划有效地改善了SMC和MCI的老年人口语学习和记忆.
- 积极的效果表明该计划的有效性超出了实践效果.
- 基线表现,性别和合规率预测了记忆改善的程度.
相关概念视频
Cognitive Development During Adulthood
288
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
288
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
209
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
209
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Dementia
167
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
167


